Inhibition of Nitric Oxide–Stimulated Vasorelaxation by Carbon Monoxide-Releasing Molecules

Antonia Marazioti, Mariarosaria Bucci, Ciro Coletta, Valentina Vellecco, Padmamalini Baskaran, Csaba Szabo, Giuseppe Cirino, Ana Rita Marques, Bruno Guerreiro, Ana M.L. Gonçalves, João D. Seixas, Annie Beuve, Carlos C. Romão, Andreas Papapetroupolos

Objective—Carbon monoxide (CO) is a weak soluble guanylyl cyclase stimulator, leading to transient increases in cGMP and vasodilatation. The aim of the present work was to measure the effect of CO-releasing molecules (CORMs) on the cGMP/nitric oxide (NO) pathway and to evaluate how selected CORMs affect NO-induced vasorelaxation.

Methods and Results—Incubation of smooth muscle cells with some but not all of the CORMs caused a minor increase in cGMP levels. Concentration-response curves were bell-shaped, with higher CORMs concentrations producing lower increases in cGMP levels. Although exposure of cells to CORM-2 enhanced cGMP formation, we observed that the compound inhibited NO-stimulated cGMP accumulation in cells and NO-stimulated soluble guanylyl cyclase activity that could be reversed by superoxide anion scavengers. Reactive oxygen species generation from CORMs was confirmed using luminol-induced chemiluminescence and electron spin resonance. Furthermore, we observed that NO is scavenged by CORM-2. When used alone CORM-2 relaxed vessels through a cGMP-mediated pathway but attenuated NO donor-stimulated vasorelaxation.

Conclusion—We conclude that the CORMs examined have context-dependent effects on vessel tone, as they can directly dilate blood vessels, but also block NO-induced vasorelaxation. (Arterioscler Thromb Vasc Biol. 2011; 31:00-00.)

Key Words: nitric oxide ■ pharmacology ■ vascular biology ■ cGMP ■ carbon monoxide

Carbon monoxide (CO), which was previously considered only as a highly toxic and life-threatening pollutant, has been recognized as a signaling molecule having regulatory roles in many physiological and pathophysiological processes within the cardiovascular, immune, and nervous systems.1,2 It is generated in mammalian tissues via the endogenous degradation of heme by a family of constitutive (heme oxygenase-2 and heme oxygenase-3) and inducible (heme oxygenase-1) heme oxygenase enzymes.3 CO gas binds to heme-containing proteins and exerts antiinflammatory and antioxidant effects.3,4 In the cardiovascular system, CO exhibits vasodilatory properties, prevents endothelial cell apoptosis, controls vascular smooth muscle cell proliferation, and inhibits platelet aggregation.3–5

It has been suggested that CO can be used as a therapeutic agent; testing the beneficial actions of CO has been facilitated by the discovery of molecules that release CO under appropriate conditions.1,6 Initial CO-releasing molecules (CORMs) were transition metal carbonyls soluble only in organic solvents and required the use of physical or strong chemical stimuli to release CO.7,8 More recently, water-soluble CORMs have been reported that liberate CO in a controlled fashion in biological systems and have the potential to deliver it to tissues and organs.9,10 Several uses have been proposed for CORMs, ranging from inflammatory diseases and vascular dysfunction to tissue ischemia, organ rejection, and sepsis.1 In the cardiovascular system, CORMs recapitulate many of the effects of CO gas. CORMs induce vessel relaxation in isolated aortic tissue and prevent coronary vasoconstriction, as well as acute hypertension in vivo.11

Similar to nitric oxide (NO), CO can activate the heme-protein soluble guanylyl cyclase (sGC), but only weakly; CO is reported to enhance sGC activity by 3- to 4-fold compared with the maximal 200-fold activation triggered by NO.12 On activation, sGC converts GTP to the second messenger molecule cyclic guanosine monophosphate (cGMP), which has an impact on many cellular functions.13 For example, sGC is important in lowering smooth muscle tone and...
preventing platelet aggregation and leukocyte adhesion to the vessel wall.\textsuperscript{13–15}

In spite of the observations that CORMs reduce vessel tone, the potential interactions between CORMs and vasodilators that activate sGC (ie, NO donors) have not been studied. To this end, we have synthesized several CORMs and determined their ability to alter cGMP levels in cells and to modulate NO-stimulated cGMP formation and vasodilation.

Methods

Synthesis of ALFs and Detection of CO Release

The metal carbonyl CORMs (ALFXXX) were synthesized according to published or modified procedures for the synthesis of related complexes (see supplemental material, available online at http://atvb.ahajournals.org). All compounds were characterized by FTR, 1H nuclear magnetic resonance, and C,H,N analysis. The compounds were prepared, purified, and kept under N<sub>2</sub> atmosphere in the dark. The solutions of CORMs were freshly prepared before the experiments by dissolving the compound in the appropriate solvent. The release of CO from the metal carbonyl complexes (ALFXXX) under normoxic conditions was assessed by a chromatographic method (see supplemental material).

Cell Culture

Rat aortic smooth muscle cells (RASMCs) were isolated from 12- to 14-week-old male Wistar rats, 5 rats per isolation, as previously described.\textsuperscript{16} More than 95% of cells isolated stained positive for smooth muscle \(\alpha\)-actin. Cells between passages 2 and 5 were used for all experiments. RASMCs were routinely cultured in Dulbecco’s modified Eagle’s medium containing 4.5 \(\text{g}\)/L glucose and supplemented with 10% fetal bovine serum and antibiotics.

Determination of cGMP Levels in RASMCs

RASMCs were plated in 24-well plates. Cells were washed twice with Hank’s balanced salt solution and incubated in Hank’s balanced salt solution in the presence of IBMX (1 \(\text{mmol}\)/L) for 5 minutes. Cells were then treated with vehicle, tempol (1 \(\text{mmol}\)/L), sodium nitroprusside (SNP) (10 \(\mu\text{mol}\)/L), diethylamine NONOate (DEA/NO) (1 \(\mu\text{mol}\)/L), or CORMs at various concentrations (1 to 100 \(\mu\text{mol}\)/L) for 15 minutes. Media were then aspirated, and 200 \(\mu\text{L}\) of 0.1 N HCl was added into each well to extract cGMP. After 30 minutes, HCl extracts were collected and centrifuged at 600g for 10 minutes to remove debris. The supernatants were directly analyzed for cGMP by enzyme immunoassay.

Determination of sGC Activity

Guanylyl cyclase activity was determined by formation of \([\alpha-32\text{P}]\text{cGMP}\) from \([\alpha-32\text{P}]\text{GTP}\). In short, reactions were performed for 10 minutes at 30°C in a final volume of 100 \(\mu\text{L}\). In a 50 \(\text{mmol}\)/L of purified sGC (10 ng/\(\mu\text{L}\)) was used in each assay reaction.

Assessment of ROS Production by CORMs

Chemiluminescence was used to measure ROS production by freshly prepared CORMs. L-012 (8-amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4-(2H,3H)dione sodium salt) is a very sensitive chemiluminescence probe used to detect reactive oxygen and nitrogen species formation. Various CORMs (1 to 300 \(\mu\text{mol}\)/L) were added to 40 \(\mu\text{L}\) of a PBS buffer containing 400 \(\mu\text{mol}\)/L L-012. L-012-enhanced chemiluminescence was immediately measured with a chemiluminesometer (Luminoskan, Labsystems, Melbourne, Victoria, Australia) and reported as relative light units. In some cases, 4-hydroxy-2,2,6,6-tetramethylpiperidinioxy (tempol) (1 \(\text{mmol}\)/L) was added to the mixture.

NO Quantification in Solution in the Presence of CORM-2

The release of NO was measured using an amperometric NO-specific probe (ISO-NOP) connected to the single channel free radical analyzer (TBR 1025, World Precision Instruments). A 4-channel recording system (Laboratory-Trac-4/16, World Precision Instruments) was used to digitize the analog signal from the probe. The ISO-NOP sensor was calibrated by mixing NaNO<sub>2</sub> solution of desired concentration with H<sub>2</sub>SO<sub>4</sub> (0.1 mol/L) and NaI (0.1 mol/L). The release of NO by DEA/NO in phosphate buffer, pH 7.4, was then monitored continuously. Cumulative concentration responses curves to DEA/NO were performed in the presence of vehicle or CORM-2 (10 and 100 \(\mu\text{mol}\)/L); the solution was constantly bubbled with N<sub>2</sub> to remove atmospheric oxygen.

Assessment of Hydroxyl Production by ALF186, ALF409, and ALF436

The formation of oxygen-based radicals and ROS in solution from the reaction between low-oxygen-state complexes and O<sub>2</sub> was tested in electron spin resonance experiments using BMPO as a spin trap.\textsuperscript{17} A stock solution of each CORM was prepared by dissolving the compound in 1 \(\text{mL}\) of deoxygenated distilled water (MeOH was used in the case of ALF436) under N<sub>2</sub>. Another stock solution of BMPO was prepared with a concentration of 250 \(\mu\text{mol}\)/L. An aliquot was taken from the CORM solution and 100 \(\mu\text{L}\) from the BMPO solution to a closed vial under N<sub>2</sub> and deoxygenated distilled water was added to make 1 \(\text{mL}\) total volume. The final concentration of CORM was 200 \(\mu\text{mol}\)/L, whereas the final concentration of BMPO was 12.5 \(\mu\text{mol}\)/L for the ALF186 experiment and 25 \(\mu\text{mol}\)/L for the others. ALF409 and ALF436. A sample was taken from this solution, and a control spectrum was acquired before bubbling O<sub>2</sub>. Oxygen was then bubbled in the solution for 3 to 4 minutes, and another sample was taken and analyzed. The experiment was performed in a quartz, planar, electron spin resonance cell, at room temperature, microwave power of 2 mW, modulation frequency 100 kHz, modulation amplitude 0.1 mT.

Aortic Ring Preparation

Male Wistar rats (250 to 300 g; Harlan, Bresso, Italy) of 8 to 10 weeks of age were euthanized, and the thoracic aorta was rapidly dissected and cleaned from fat and connective tissue. Rings were denuded of the endothelium and placed in organ baths filled with oxygenated (95% \(\text{O}_2\) to 5% \(\text{CO}_2\)) Krebs solution at 37°C, mounted to isometric force transducers, and connected to a Graphic recorder. Rings were initially stretched until a resting tension of 0.5 g was reached and allowed to equilibrate for at least 30 minutes, during which tension was adjusted. In each experiment aortic rings were first challenged with phenylephrine (PE) (1 \(\mu\text{mol}\)/L) until the responses were reproducible. Aortic rings were contracted with PE (1 \(\mu\text{mol}\)/L). Once the plateau was reached, a cumulative concentration-response curve to DEA/NO or \(\text{S-nitroso-}\text{N-acetyl-L,L-penicillamine}\) (SNAP) (1 \(\mu\text{mol}\)/L to 10 \(\mu\text{mol}\)/L) and CORM-2 (1 \(\mu\text{mol}\)/L to 200 \(\mu\text{mol}\)/L) were performed. In another set of experiments, rings were pretreated with 200 \(\mu\text{mol}\)/L CORM-2 for 15 minutes at resting tension, and then PE was added to constrict the preparation. The increase in tension induced by PE after CORM-2 preincubation was not significantly different from control. DEA/NO or SNAP cumulative concentration-response curves were then performed in the presence or absence of SNAP (100 \(\mu\text{mol}\)/L) or tempol (3 \(\mu\text{mol}\)/L).

Statistical Analysis

Data are expressed as means±SE. Statistical comparisons between groups were performed using 1- or 2-way ANOVA (data from cell culture experiments were analyzed with 1-way ANOVA, whereas...
data from vasorelaxation studies were analyzed by 2-way ANOVA) followed by a post hoc test or Student t test as appropriate. Differences were considered significant at P<0.05. GraphPad Prism software (version 4.02, GraphPad Software, San Diego, CA) was used for all the statistical analysis.

Results

Detection of CO Liberated From CORMs

CO release form CORMs in cell-culture medium (RPMI/fetal bovine serum) is summarized in the Table. Some CORMs (ALF186, ALF409, ALF411, ALF432, and ALF436) liberate >0.9 molar equivalents of CO after 2 hours. Interestingly, when dissolved in PBS (pH 7.4), CO liberation was enhanced in all cases, with the exception of ALF411. This indicates that molecules present in the RPMI/fetal bovine serum medium protect CORMs complexes from decomposition or quench the CO formed. ALF411 behaves differently because it dissolves in RPMI/fetal bovine serum, but is completely insoluble in PBS. As expected, once in solution its stability decreases and CO release occurs. The role of O2 as the trigger for the liberation of CO from these complexes is quite clear because under anaerobic conditions (N2), CO release is blocked in all cases except that of ALF409, where a small amount of CO is still liberated. In contrast to other CORMs and in accordance to previous reports,1 the well-known Ru(II) CORMs, CORM-2 [Ru(CO)3Cl2]2 and CORM-3 [Ru(CO)3Cl(H-NCH2COO)] do not release any CO in the headspace. On the contrary, they slowly release CO2 over 24 hours in solution.18

Effect of CORMs on cGMP Levels in Cultured Cells

Exposure to a nonsaturated CO solution (100 μmol/L) caused a small, ~50%, increase in cGMP levels in rat aortic smooth muscle cells (Figure 1A). For comparison, under the same conditions, stimulation of cells with the NO donor at 10 μmol/L leads to a 30-fold increase in cGMP accumulation (Figure 1B). Most CORMs when used at 1 and 10 μmol/L failed to increase cGMP levels in smooth muscle cells (Supplemental Table I); among the compounds tested, ALF436 increased cGMP by 3-fold at the lowest concentration used. For the more widely studied CORM-2 and CORM-3, higher concentrations were also used. Cells treated with CORM-2 showed a bell-shaped increase in cGMP accumulation, whereas exposure to CORM-3 caused an inhibition at the highest concentration used (300 μmol/L) (Figure 1C and 1D). The ability of CORM-2 to stimulate cGMP levels was blocked by the sGC inhibitor ODQ or by incubation of cells with hemoglobin (Supplemental Figure IA.)

Table. Spontaneous Release of CO and cGMP Production by CORMs

<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>Equivalent CO Released in RPMI/PBS in Air</th>
<th>Equivalent CO Released in PBS in Air</th>
<th>Equivalent CO Released in PBS in N2</th>
<th>Time (h)</th>
<th>cGMP Production, Percentage of 1 μmol/L Vehicle</th>
<th>cGMP Production, Percentage of 10 μmol/L Vehicle</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALF186</td>
<td><img src="https://example.com/structures/ALF186.png" alt="ALF186 Structure" /></td>
<td>1.9</td>
<td>2.7</td>
<td>0.1</td>
<td>2</td>
<td>145.77±30.7</td>
<td>127.78±19.04</td>
</tr>
<tr>
<td>ALF409</td>
<td><img src="https://example.com/structures/ALF409.png" alt="ALF409 Structure" /></td>
<td>0.9</td>
<td>1.3</td>
<td>0.1</td>
<td>2</td>
<td>93.76±10.23</td>
<td>89.45±14.39</td>
</tr>
<tr>
<td>ALF411</td>
<td><img src="https://example.com/structures/ALF411.png" alt="ALF411 Structure" /></td>
<td>1.3</td>
<td>0.0</td>
<td>0.0</td>
<td>2</td>
<td>67.56±11.98</td>
<td>64.81±11.99</td>
</tr>
<tr>
<td>ALF432</td>
<td><img src="https://example.com/structures/ALF432.png" alt="ALF432 Structure" /></td>
<td>1.7</td>
<td>3.0</td>
<td>0.0</td>
<td>2</td>
<td>100.19±2.34</td>
<td>86.60±5.86</td>
</tr>
<tr>
<td>ALF436</td>
<td><img src="https://example.com/structures/ALF436.png" alt="ALF436 Structure" /></td>
<td>0.9</td>
<td>1.5</td>
<td>0.0</td>
<td>2</td>
<td>335.28±108.57</td>
<td>152.42±20.29</td>
</tr>
<tr>
<td>CORM-2</td>
<td><img src="https://example.com/structures/CORM-2.png" alt="CORM-2 Structure" /></td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2</td>
<td>231.32±31.91</td>
<td>298.51±82.82</td>
</tr>
<tr>
<td>CORM-3</td>
<td><img src="https://example.com/structures/CORM-3.png" alt="CORM-3 Structure" /></td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2</td>
<td>87.75±8.14</td>
<td>102.53±12.3</td>
</tr>
</tbody>
</table>

Shown are the molar equivalents of CO released by the indicated CORMs in RPMI/FBS or PBS. Experiments were performed at room temperature under normoxic and anoxic conditions. CO released in the headspace of a closed vial was determined by a gas chromatographic method that uses a thermal conductivity detector. Confluent rat aortic smooth muscle cell were treated with vehicle or a CORM (1 and 10 μmol/L) in the presence of IBMX for 15 min. cGMP was extracted and measured as described. Data are expressed as percentage of the respective vehicle, which was set as 100%; n=8 to 12; *P<0.05 compared with vehicle. CORM indicates CO-releasing molecule.
and IB). Moreover, the inactive form of CORM-2 (lacking the CO groups) did not alter cGMP accumulation (Supplemental Figure IC). The above data taken together suggest that CORM-2 increased cGMP accumulation through CO-dependent activation of sGC.

Effect of CORMs on Recombinant sGC Activity

We next evaluated whether CORMs exert a direct effect on sGC activity by using recombinant rat sGC. In contrast to the increase in cGMP accumulation observed with cultured cells, no increase in sGC activity was observed after incubation with CORM-3 and CORM-2 at the concentrations used (Figure 2A). On the other hand, the NO-stimulated sGC activity was markedly reduced in a concentration-dependent manner by these CORMs (Figure 2B).

Generation of ROS and Scavenging of NO by CORMs

To study the mechanism through which CORMs reduce NO-stimulated cGMP formation, we initially measured the ability of CORMs to generate ROS. ROS production from CORM-2 was concentration dependent, plateauing at a 100 µmol/L concentration of this CORM, and could be abolished by addition of tempol, an O2 scavenger (Figure 3A and 3B). Two other molybdenum-based CORMs, ALF186 and ALF436, also increased ROS production (Supplemental Figure IIA and IIB). The ALF186- and ALF436-induced ROS released was inhibited by tempol (Supplemental Figures IIB and IVB). In a separate series of experiments, we observed that the electron spin resonance spectra obtained for the solutions of ALF186 (or CORM-3, ALF409, ALF436; data not shown) after bubbling O2 revealed a very strong and clean signal assignable to the hydroxyl adduct of BMPO (Figure 3C). Thus, although CO from CORMs activates sGC in an NO-independent and, thus, superoxide-insensitive manner, the ROS generated by CORMs would be expected to inhibit NO-stimulated guanylyl cyclase activity.

To assess whether CORM-2 can react with NO, we measured NO using an NO electrode (Figure 3D). In these experiments, we observed that CORM-2 attenuated the amount of NO in solution released by DEA/NO in a concentration-dependent manner. When NO levels were measured in a 10 µmol/L DEA/NO solution, they were found to be decreased by 80% when a 10-fold excess of CORM-2 was present. Similar observations were made using SNP as a donor (data not shown). Using a different experimental setup, we observed that CORM-2 quenched NO; scavenging of NO by CORM-2 was favored when CORM-2 is present in excess (>10-fold) relative to NO (Supplemental Figure V).

Interaction of CORMs With NO Donors in Cells

To study whether CORM-2 reduces NO donor-stimulated cGMP accumulation in cells, RASMCs were exposed to SNP CORM-2 was concentration dependent, plateauing at a 100 µmol/L concentration of this CORM, and could be abolished by addition of tempol, an O2 scavenger (Figure 3A and 3B). Two other molybdenum-based CORMs, ALF186 and ALF436, also increased ROS production (Supplemental Figure IIA and IIB). The ALF186- and ALF436-induced ROS released was inhibited by tempol (Supplemental Figures IIB and IVB). In a separate series of experiments, we observed that the electron spin resonance spectra obtained for the solutions of ALF186 (or CORM-3, ALF409, ALF436; data not shown) after bubbling O2 revealed a very strong and clean signal assignable to the hydroxyl adduct of BMPO (Figure 3C). Thus, although CO from CORMs activates sGC in an NO-independent and, thus, superoxide-insensitive manner, the ROS generated by CORMs would be expected to inhibit NO-stimulated guanylyl cyclase activity.

To assess whether CORM-2 can react with NO, we measured NO using an NO electrode (Figure 3D). In these experiments, we observed that CORM-2 attenuated the amount of NO in solution released by DEA/NO in a concentration-dependent manner. When NO levels were measured in a 10 µmol/L DEA/NO solution, they were found to be decreased by 80% when a 10-fold excess of CORM-2 was present. Similar observations were made using SNP as a donor (data not shown). Using a different experimental setup, we observed that CORM-2 quenched NO; scavenging of NO by CORM-2 was favored when CORM-2 is present in excess (>10-fold) relative to NO (Supplemental Figure V).
Effect of CORM-2 on Vascular Tone

CORM-2 administration caused a concentration-dependent relaxation that reached approximately 60% relaxation at the highest concentration used (Figure 5A). CORM-2-induced relaxation was abolished by ODQ, suggesting that the relaxation is mediated by sGC. Exposure to the NO donor DEA/NO led to a full relaxation that was observed at a much lower concentration than the one needed for maximal CORM-2 relaxation (Figure 5B). To assess whether CORM-2 could interfere with the vasodilation triggered by exogenously administered NO, relaxation curves to DEA/NO were repeated in the presence of a maximally dilating CORM-2 concentration. It should be noted that the contractile response to PE was not significantly affected by the preincubation with CORM-2. This might be due to the fact that the CORM-2-induced vasodilation is short-lived and is no longer observed after the preincubation, or due to the fact that the vasorelaxing action of CORM-2 is only displayed when this agent is applied to a tissue after, but not before, it develops an elevated tone. In line with what we observed in the experiments with purified sGC and cultured cells, NO-induced relaxation was attenuated by CORM-2. The inhibitory effect of CORM-2 in NO-induced vasodilation was reduced by SOD (Figure 5C) and tempol (Figure 5D). Similar results were obtained using a different NO donor SNAP. In a manner analogous to that observed with SNP responses in cultured cells, the vasorelaxing action of SNP was inhibited to a greater extent by CORM-2 (Supplemental Figure VII).

Discussion

The derivatives of the fragment fac-[RuII(CO)3]3+, CORM-2, and CORM-3 introduced by Motterlini and Otterbein are the most commonly reported examples of metal carbonyl complexes used as vehicles to deliver CO to cells and tissues.1 The CO releasing capacity of these compounds has been measured by their ability to rapidly (<1 minute) transfer 1
CO to deoxy-Mb, forming carbonmonoxy-myoglobin. However, we and others have observed that these compounds do not release CO as a free gas. Thus, CO from CORM-2 and CORM-3 is assumed to be first transferred to a biological molecule forming an intermediate that delivers CO in living systems.

In the present study, we introduced a different group of CORMs based on zero-valent molybdenum carbonyls. In contrast to the previous Ru(II) complexes, these Mo(0) compounds are able to release CO as a free gas to their biological environment once they are activated by molecular oxygen.

All but one of the molybdenum-based CORMs, in spite of releasing measurable amounts of CO in cell culture media, failed to stimulate cGMP production in cultured vascular smooth muscle cells. The one that did (ALF436) increased cGMP only marginally, and this effect was lost when higher concentrations were used. From our in vitro studies, it became apparent that cGMP accumulation in cultured smooth muscle cells is not a good bioassay to test for biological activity of molybdenum-based CORMs. Among the ruthenium-based CORMs (CORM-2 and CORM-3), neither of which release CO to the headspace but rather transfer CO to heme-containing biological molecules, only CORM-2 increased cGMP accumulation. However, CORM-3 has been reported to promote vasodilation in an ODQ-inhibitable manner and to increase cGMP levels in vascular tissue. The cGMP-elevating effect of CORM-3 was shown to be diminished by endothelium removal or endothelial nitric oxide synthase inhibition, suggesting that CORM-3 might be acting, at least in part, by enhancing endogenous NO release rather than through a direct effect on sGC. Of note, cGMP-independent mechanisms of CORM-induced smooth muscle relaxation have also been shown to exist. These are mediated through big conductance calcium-activated potassium channels: the opening of these channels leads to membrane hyperpolarization, which in turn closes voltage-dependent calcium channels, reduces calcium levels, and relaxes smooth muscle.

To examine whether CORMs directly activate sGC, we tested the 2 most studied CORMs to date (CORM-2 and CORM-3) for their ability to stimulate recombinant sGC. In line with previous observations, CORM-3 did not enhance sGC activity in vitro; neither did CORM-2. CORM-3 has been shown to increase sGC activity in the presence of the sGC sensitizer YC-1. The fact that CORM-2 increased cGMP formation in cells but not in the sGC activity assay could be explained by the existence of an endogenous YC-1-like sGC sensitizer in smooth muscle cells. Alternatively, the formation of an intermediate/metabolite might be required for the transfer of CO from these CORMs to sGC and this only occurs in cells. Surprisingly, we found that both CORMs markedly and dose-dependently inhibited NO-stimulated sGC activity. This inhibitory action of CORM-2 and CORM-3 on NO-stimulated sGC has not been reported before and could be explained by (1) a partial agonist effect of CO on sGC activation, (2) ROS generation by the CORMs that inactivates NO, or (3) quenching of NO by the transition metal complexes. Experiments were therefore designed to test the above-mentioned hypotheses.
and removed it from the solution in a time and concentration-dependent manner. Thus, when ruthenium-based CORMs are used as pharmacological tools, they would be expected to lower NO concentrations in tissues.

It has been previously reported that CORM-2 relaxes precontracted vessels.\textsuperscript{11} In agreement with these observations, we observed a vasorelaxing effect of this CORM that was first evident at 100 \( \mu \)mol/L and reached an \( \approx 60\% \) decrease in vessel tone at 200 \( \mu \)mol/L. In addition, inhibition of sGC abolished the effects of CORM-2, indicating that sGC activation and cGMP elevation mediate the vasodilatory effect of CORM-2 in this preparation. However, in a manner analogous to that seen with recombinant sGC and cells, we also observed that CORM-2 attenuated NO donor–induced vasorelaxation. The magnitude of the inhibitory responses of CORM-2 toward NO-driven dilation varied with the donor vasorelaxation. The magnitude of the inhibitory responses of CORM-2 in this preparation. However, in a manner analogous to that seen with recombinant sGC and cells, we also observed that CORM-2 attenuated NO donor–induced vasorelaxation. The magnitude of the inhibitory responses of CORM-2 toward NO-driven dilation varied with the donor used; responses to SNAP were affected more than those to DEA/NO. In agreement with what we observed with purified sGC and cultured cells we saw that scavenging O\(_2\) reduced the defect in relaxation caused by CORM-2. However, the effect of both SOD and tempol in preventing the effects of CORM-2 on NO-stimulated dilation was weaker compared with that observed with the purified enzyme or cells. Given that tissues have a higher antioxidant capacity, the inhibitory action of CORM-2 in aortic ring relaxations might be mainly due to scavenging of the NO released by CORM-2; the CORM-2:DEA/NO ratio was, for most of the concentration-response curves in the relaxation experiments, much higher than the CORM-2:NO donor ratio in the activity experiments (CORM-2:DEA/NO ratio of 10 for the sGC activity assays); thus, even if ROS are removed by antioxidants, NO would still be scavenged in the organ bath experiments by CORM-2.

In summary, we have shown that CORMs do not activate purified sGC, but are capable of elevating cGMP levels in cells and causing sGC-mediated vasorelaxation. More importantly, we have shown that currently available CORMs based on transition metal carbonyl scaffolds inhibit NO-induced signaling and vasorelaxation through multiple mechanisms that include ROS generation and direct scavenging of NO. The final biological effect of any CORM would depend on the amount of CO released by the CORM, the levels of endogenously produced NO, the concentration of CORM present that might react with NO, the amount and species of ROS produced as a byproduct of CORM breakdown, and the levels of antioxidants enzymes and chemicals present in the tissues. Design of improved, “second-generation” CORMs devoid of unwanted properties (ROS generation, NO scavenging) is needed for this class of compounds to be used in establishing the therapeutic utility of CO in preclinical and clinical models.

**Acknowledgments**

We thank Conceição Almeida, ITQB, for elemental analysis.

**Sources of Funding**

Dr Seixas thanks Fundação para a Ciência e Tecnologia, Portugal for Doctoral Grant SFRH/BDE/15501/2004. The nuclear magnetic resonance spectrometers are part of the National NMR Network and were purchased in the framework of the National Program for Scientific Re-equipment, contract REDE/1517/RMN/2005, with funds from POCI 2010 (FEDER) and Fundação para a Ciência e a Tecnologia. This work was supported by grants from the Greek Ministry of Education and the Secretariat of Research and Technology (to A.P.), by Grant S661 from the Shriners Burns Hospitals (to C.S.), and by the COST Action BM11005 (European Network on Gasotransmitters).

**Disclosures**

None.

**References**


Inhibition of Nitric Oxide–Stimulated Vasorelaxation by Carbon Monoxide-Releasing Molecules

Antonia Marazioti, Mariarosaria Bucci, Ciro Coletta, Valentina Vellecco, Padmamalini Baskaran, Csaba Szabo, Giuseppe Cirino, Ana Rita Marques, Bruno Guerreiro, Ana M.L. Gonçalves, João D. Seixas, Annie Beuve, Carlos C. Romão and Andreas Papapetropoulos

Arterioscler Thromb Vasc Biol. published online August 11, 2011;
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/early/2011/08/11/ATVBAHA.111.229039

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2011/08/11/ATVBAHA.111.229039.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/
SUPPLEMENT MATERIAL

Materials and Methods

Materials

DMEM, HBSS, and FBS were obtained from GIBCO-BRL (Paisley, UK). Cell culture flasks and plates were obtained from Greiner Labortechnik (Frickenhausen, Germany). Dulbecco’s PBS, penicillin, and streptomycin were from Biochrom (Berlin, Germany). cGMP enzyme immunoassay kits were purchased from Assay Designs (Ann Arbor, MI). Tempol, L-NAME, ODQ, IBMX, S-nitroso-N-acetylpenicillamine (SNAP), 1,1-diethyl-2-hydroxy-2-nitroso-hydrazine (DEA/NO), superoxide dismutase (SOD), sodium nitroprusside (SNP), CORM-2 and all other chemical reagents were purchased from Sigma (St. Louis, MO). L-012 (8-amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4-(2H,3H)dione sodium salt) was purchased from Wako Pure Chemical Industries (Osaka, Japan). The spin trap NWT-BMPO, >99% was purchased from Northwest Life Sciences Specialties, LLC (Vancouver, WA).

Synthesis of ALFs and detection of CO release

The metal carbonyl CO-RMs ALF186, ALF411, CORM-3 were synthesized according to published procedures: ALF436 was adapted from van Staveren et al.; ALF409 was prepared by a modification of the method reported for the analogue [Et₄N]⁺ salt and ALF432 was prepared in a similar way as described below.

Preparation of tricarbonyl(N-(p-carboxy-benzyl)bis(2-picoly)amine)Mo(0) (ALF436)

The N-(p-carboxy-benzyl)bis(2-picoly)amine ligand was prepared as follows:
To a clear THF solution of methyl-4-(bromomethyl)benzoate (1.13 g, 4.85 mmol; 229.08 g/mol) was added at once the yellow di-2-(picoly)amine (0.903 ml; 4.85
mmol; 1.107 g/ml; 199.25 g/mol) at room temperature. The solution turns light yellow. Triethylamine (675 μL; 4.85 mmol; 0.727 g/ml; 101.19 g/mol) is added and the solution turns immediately deep yellow. The mixture was allowed to reach room temperature and subsequently filtered to remove a white precipitate. After removal of the solvent under reduced pressure, the orange oily residue was dissolved in diethyl ether (40 ml) and filtered to remove some more precipitate. Evaporation of the solvent gives a dark orange oil which was used in the next step.

**1H NMR** (CDCl₃, 400 MHz, rt; δ in ppm): δ = 8.49 (d,2H), 7.98 (d,2H), 7.64 (dt,2H), 7.53 (d,2H), 7.48 (d,2H), 7.12 (tt,2H), 3.89 (s,3H), 3.81 (s,4H), 3.75 (s,2H). Note: There is a 5% of the di-2(-picolyl)amine used in slight excess;

The orange oil was dissolved in methanol (20 ml) and a solution of aqueous NaOH (0.8 g in 5 ml H₂O; 20 mmol; 40 g/mol) was added. The solution gets immediately darker and is stirred for two hours at room temperature. The pH was adjusted to 7 by dropwise addition of 2M HCl (50 ml HCl 37% in 250 ml water solution) followed by removal of the solvent under reduced pressure. The sticky yellow residue was ground with CHCl₃ (200 ml) followed by filtration to remove NaCl. Removal of the solvent under reduced pressure afforded an orange sticky oil to which acetonitrile (30 ml) was added, followed by vigorous stirring to dissolve all compound. A precipitate is seen after 15 minutes. The solution was placed in the refrigerator to effect further precipitation. The white precipitate was filtered and dried under vacuum. **Yield:** < 20%.

**E.A.** Calc. for N₂O₂C₂₀H₁₉: %C:72.05, %H:5.74, %N:12.60; Found: %C:72.57, %H:5.98, %N:13.04;

**1H NMR** (CDCl₃, 400 MHz, rt, δ in ppm): δ = 8.61 (d,2H), 8.01 (d,2H), 7.70 (dt, 2H), 7.60 (d,2H), 7.44 (d,2H), 7.12 (t,2H), 3.88 (s,4H), 3.77 (s,2H).

Synthesis of the complex ALF₄36:

Mo(CO)₃(η⁶-C₇H₈) (0.800 g; 2.94 mmol; 272.1117 g/mol) was dissolved in 40 ml of MeOH and added to (C₅H₄CH₂)₂NCH₂C₆H₄COOH (0.980g; 2.94 mmol; 333.39 g/mol) in 25 ml of MeOH.

The red clear solution became turbid with an abundant insoluble precipitate after 5 minutes. The reaction was carried on for 2h at room temperature. The precipitate
was allowed to rest and was filtered. It was washed with 25 ml of Et₂O and dried in vacuum giving a bright orange powder. **Yield:** 86%.

**IR (KBr/cm⁻¹; C≡O):** 1899(vs), 1759(s);

**E.A.** Calc. for C₂₃H₁₉N₃MoO₅: %C=53.81, %H=3.73, %N=8.19; Found: %C=54.01, %H=3.79, %N=7.79;

**¹H NMR ((CD₃)₂CO, 400MHz, rt, δ in ppm):** δ = 8.85 (d,2H); 8.14 (d,2H), 7.88 (d,2H), 7.61 (d,2H), 7.21 (d,2H), 7.11 (d,2H), 4.80 (s,2H), 4.73 (d,2H), 3.92 (d,2H).

**Preparation of Na₅[Mo(CO)₃(citrate)] (ALF409)**

The general procedure is presented for Na₅[Mo(CO)₃(citrate)]:

Sodium citrate dihydrate (0.844 g; 2.801 mmol; 294.1 g/mol) and (η⁶-C₇H₈)Mo(CO)₃ (0.780 g; 2.866 mmol; 272.12 g/mol) were suspended in 100 ml of dry MeOH and stirred for 24 hours at room temperature. The light orange solution was filtered and concentrated under vacuum. This was transferred to another schlenk, partially filled with a large amount of Et₂O. A flocculate precipitate was obtained and filtered. It was washed with Et₂O and dried in vacuum to afford a light brown powder. **Yield:** 74%.

**IR (KBr/cm⁻¹):** 1984(w), 1901(s) (C≡O); 1754(br), 1599(br), 1410(m) (C=O);

**E.A.** Calc. for MoC₉H₅O₁₀Na₅.2(CH₃OH): %C:26.31, %H:2.61; Found: %C:26.49, %H:2.21;

**¹H NMR (D₂O, 400MHz, rt, δ in ppm):** δ = 2.67 (s,1H); 2.63 (s,2H), 2.57 (s,1H), 2.53 (s,1H).

**Preparation of Na₅[Mo(CO)₃(diethylenetriaminepentaacetate)] (ALF432)**

The compound was prepared as ALF409 above.

**Yield:** 80%;

**IR (KBr/cm⁻¹):** 1897(s) (C≡O); 1753(br), 1600(br), 1401(m) (C=O);

**E.A.** Calc. for MoC₁₇H₁₈O₁₃N₃Na₅(CH₃OH): %C=30.23, %H=3.10, %N=5.87; Found: %C=29.83, %H=3.66, %N=5.66;

**¹H NMR (D₂O, 400MHz, rt, δ in ppm):** δ = 2.8-3.9 (broad band).
The solutions of CO-RMs were freshly prepared before the experiments by dissolving the compound in the appropriate solvent. The release of CO from the metal carbonyl complexes (ALFXXX) under normoxic conditions was assessed by a chromatographic method. Typically, 10-30mg of each compound were incubated with 3ml of RPMI/FBS containing 10% Fetal Bovine Serum, with magnetic stirring in a closed vessel at 37°C, in the dark. The atmosphere of this vessel was CO2 free, reconstituted air. Samples of the homogenized headspace were taken at 2hr and the amount of CO gas quantified by GC with TCD detection. Depending on the compound, the total amount of gas liberated in these experiments was in the order of 1-3 ml (Table I).

**NO Detection**

In the present study we assessed the effect of CORM-2 in the NO release by DEA/NO using an amperometric NO-specific probe (ISO-NOP) connected to the single channel free radical analyzer (TBR 1025, World Precision Instruments). A four channel recording system (Lab-Trax-4/16, World Precision Instruments) was used to digitize the analog signal from the probe. The ISO-NOP sensor was calibrated immediately before the experiment following the manufacturing specifications. Briefly, the calibration procedure involves two solutions (0.1M H2SO4 + 0.1 M KI, and 50μM NaNO2) and it is based on the following reaction

\[2\text{NaNO}_2 + 2\text{KI} + 2\text{H}_2\text{SO}_4 \rightarrow 2\text{NO} + \text{I}_2 + 2\text{H}_2\text{O} + 2\text{K}_2\text{SO}_4\]

The ISO-NOP sensor was immersed in 5ml of the solution containing iodide and a positive potential of 860 mV (Ag/AgCl reference electrode) was applied. Increasing amount of NaNO2 (12.5, 25, 50, 100, and 200 μl) were added to produce a known amount of NO. The concentration of NO generated can be calculated directly from the
stoichiometry since KI and H$_2$SO$_4$ are present in great excess and the reaction goes to completion. NO diffuses across the gas permeable (NO-selective) membrane and is oxidized at the working electrode surface producing a redox current which is measured. Once the calibration procedure ended the probe was immersed in 5ml of phosphate buffer at pH 7.4 and the release of NO by the NO donor DEA/NO was monitored continuously. Cumulative concentration response curves to DEA/NO were performed by adding increasing DEA/NO concentrations in presence or absence of CORM-2 (10 and 100 µmol/L) under constant nitrogen bubbling. A higher DEA/NO concentration was added once a plateau was reached (typically within 2-3min). Vehicle (DMSO) or CORM-2 were added immediately before the first addition of DEA/NO.

**NO quantification in solution in the presence of CO-RM**

NO in solution was determined by measuring nitrite (NO$_2^-$) concentration using the Griess reagent. As NO reacts with oxygen producing NO$_2^-$ in equimolar concentrations, the reaction between NO and CORM-2 was performed in the absence of air, in deoxygenated vials using deoxygenated water. At each time point an aliquot of the reaction mixture was removed from the vials. A NO saturated solution (2 mM) was mixed with different concentrations of CORM-2 [solubilized in 10% dimethyl sulfoxide (DMSO)] in order to have the following ratios of CORM-2 to NO: 1:1 (0.5 mM CORM-2: 0.5 mM NO); 10:1 (5 mM CORM-2: 0.5 mM NO) and 20:1 (10 mM CORM-2: 0.5 mM NO). After 5-60min a sample of each reaction mixture was removed from the vial and allowed to stand in room air; some samples were incubated with nitrate reductase (0.0025U/ml nitrate reductase) for 30 min at 30°C to convert nitrate to nitrite. After the addition of the Griess reagent, the mixtures were left at
room temperature for 10 minutes and then the absorbance of the solutions was measured at 550 nm in a microplate reader. Standard curves were constructed using NaNO₂.

**Assessment of hydroxyl production by ALF186, ALF409 and ALF436**

The formation of oxygen based radicals and ROS species in solution from the reaction between low oxidation state complexes and O₂, was tested in ESR experiments using BMPO as a spin trap⁶. A stock solution of each CO-RM was prepared by dissolving the compound in 1 mL of deoxygenated distilled water (MeOH was used in the case of ALF436) under N₂. Another stock solution of BMPO was prepared with a concentration of 250 mM. An aliquot was taken from the CO-RM solution and 100 μL from the BMPO solution to a closed vial under N₂ and deoxygenated distilled water added to perform 1 ml total volume. The final concentrations of CO-RM were 200µM whereas the final concentration of BMPO was 12.5 mM for the ALF186 experiment and 25mM for the other ALF409 and ALF436. A sample was taken from this solution and a control spectrum was acquired before bubbling O₂. Oxygen was then bubbled in the solution for 3-4 min and another sample was taken and analyzed. The experiment was performed in a quartz, planar, ESR cell, at room temperature, microwave power of 2 mW, modulation frequency 100 kHz, modulation amplitude 0,1 mT.

**Aortic ring preparation**

Male Wistar rats (250–300 g; Harlan, Bresso, Italy) of 8–10 wk of age were killed, and the thoracic aorta was rapidly dissected and cleaned from fat and connective tissue. Rings of 2–3mm length were cut, denuded of the endothelium and placed in
organ baths (2–5 ml) filled with oxygenated (95% O2-5% CO2) Krebs solution at 37°C and mounted to isometric force transducers (type 7006, Ugo Basile, Comerio, Italy) and connected to a Graphtec recorder (WR 3310). The composition of the Krebs solution was as follows (mol/l): NaCl 0.118, KCl 0.0047, MgCl2 0.0012, KH2PO4 0.0012, CaCl2 0.0025, NaHCO3 0.025, and glucose 0.010. Rings were initially stretched until a resting tension of 0.5 g was reached and allowed to equilibrate for at least 30 min during which tension was adjusted, when necessary, to a 0.5 g, and bathing solution was periodically changed. In a preliminary study, a resting tension of 0.5 g was found to develop the optimal tension to stimulation with contracting agents. In each experiment aortic rings were first challenged with PE (1μM) until the responses were reproducible. Aortic rings were contracted with PE (1μM). Once the plateau was reached, a cumulative concentration-response curve to DEA/NO or SNAP with or without CORM-2 was performed; in some experiments rings were exposed to increasing concentrations of CORM-2 (1μM-1mM) in the presence of ODQ (5μM). In another set of experiments, rings were incubated with 200μM CORM-2 and SNAP cumulative concentration-response curve was performed in the presence or absence of SOD (300IU/ml) or tempol (3mM).

**Determination of soluble guanylyl cyclase activity**

GC activity was determined by formation of [α-32P]cGMP from [α-32P]GTP as previously described using semi-purified rat sGC7. In short, reactions were performed for 10 min at 30°C in a final volume of 100 μl, in a 50 mM HEPES, pH 8.0, reaction buffer containing 500 μM GTP, 1 mM DTT, and 5 mM MgCl2. Basal and DEA-NO(1μM)-stimulated guanylyl cyclase activity was measured in the presence of CO-
RMs (10 and 100μM). To inhibit ROS production SOD (100IU/ml) was added in the mixture. Typically, 5 μl of purified sGC (10 ng/μl) was used in each assay reaction.

REFERENCES


cyclase: structural implication for the YC-1 binding site? Biochemistry 2004; 43: 3039-3048

Figure Legends

Figure I. CORM-2 stimulates cGMP by releasing CO and activating sGC in cells. Confluent RASMCs were treated with vehicle, CORM-2 10μM in the presence or absence of hemoglobin (1μM; A), or ODQ (10μM, 30min pre-treatment; B) in the presence of IBMX for 15min. In (C), cells were treated with the inactive CORM-2 (RuCl3, 20μM) in the presence or absence of DEA/NO (1μM). cGMP was extracted and measured as described in Methods section. Data are expressed as percentage of respective vehicle which was set as 100%; n=4-8; *P<0.05 from vehicle, #P<0.05 from CORM-2 or DEA/NO.

Figure II. Molybdenum-based CO-releasing molecules release ROS and reduce NO-induced cGMP accumulation. ROS release by the indicated concentration of CO-RMs was measured by chemiluminescence (A and B). RASMC were treated with vehicle, CO-RM alone (100μM), DEA/NO alone (1μM, B) or a combination of the NO-donor with CO-RM in the presence of IBMX for 15min (C and D). cGMP was extracted and measured as described in Methods section. Data are expressed as percentage of respective vehicle which was set as 100%; n=8; *P<0.05 from vehicle and #P<0.05 from DEA/NO.

Figure III. Tempol inhibits ALF186-induced ROS production and ALF186-triggered inhibition of cGMP accumulation. cGMP accumulation was measured in RASMCs in the presence of IBMX. Cells were treated with DEA/NO (1μM) or a combination of DEA/NO with ALF186 (100μM) in the presence of tempol (30min
pretreatment; 1mM; A); n=8; *P<0.05 from vehicle and #P<0.05 from DEA/NO. ROS release by ALF186 (100μM) was measured by chemiluminescence in the absence or presence of tempol (1mM; B); n=4; *P<0.05 from vehicle; #P<0.05 from ALF186.

**Figure IV. Tempol inhibits ALF436-induced ROS production and ALF436-triggered inhibition of cGMP accumulation.** cGMP accumulation was measured in RASMCs in the presence of IBMX. Cells were treated with DEA/NO (1μM) or a combination of DEA/NO with ALF436 (100μM) in the presence of tempol (30min pretreatment, 1mM; A); n=8; *P<0.05 from vehicle and #P<0.05 from DEA/NO. ROS release by ALF436 (100μM) was measured by chemiluminescence in the absence or presence of tempol (1mM; B); n=4; *P<0.05 from vehicle; #P<0.05 from ALF436.

**Figure V. CORM-2 scavenges NO.** NO was mixed with CORM-2 in deoxygenated vials and after the indicated time and aliquot was removed. The amount of NO in solution was quantified by measuring nitrite formation following air exposure. NO2− concentration was determined using the Griess reagent in the absence (A) or presence of nitrate reductase (B). The relative concentrations of CORM-2: NO used in the experiment were: 1:1; 10:1 or 20:1. The remaining NO is solution (after the reaction with CORM-2) upon exposure to air is mainly converted to NO2− since treatment with nitrate reductase did not alter the levels of NO2− detected.

**Figure VI. Tempol reduces the effect of CO-RMs on cGMP accumulation.** cGMP accumulation was measured in RASMCs in the presence of IBMX. Cells were treated with DEA/NO (1μM), CORM-2 (100μM) or a combination of both in the absence (A)
or presence (B) of tempol (30min pretreatment, 1mM); n=8; *P<0.05 from vehicle, #P<0.05 from DEA/NO; p=0.05 for DEA/NO vs DEA/NO+CORM-2 in the presence of tempol.

**Figure VII. CORM-2 inhibits SNAP-stimulated relaxation.** Rings were pre-treated with CORM-2 (200µM) or vehicle for 15min and then contracted with phenylephrine; they were then exposed to increasing concentrations of the NO donor SNAP (S-nitroso-N-acetyl-penicillamine) (A). Phylephrine-contracted rings were incubated with SOD (100IU/ml) or tempol (3mM) for 15min prior to being exposed to CORM-2 (200µM); SNAP was then added at the indicated concentration to elicit vasorelaxation. Data are mean ± SEM; n=4-6 *P<0.001 from vehicle, *P<0.001 from CORM-2.
Suppl VII

A

% relaxation

SNAP (log M)

vehicle
CORM-2

B

% relaxation

SNAP (log M)

vehicle
CORM-2
CORM-2 + SOD

C

% relaxation

SNAP (log M)

vehicle
CORM-2
CORM-2 + tempol
Table I

<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>Equiv.CD released in RPMI/FBS in air</th>
<th>Equiv.CD released in PBS in air</th>
<th>Equiv.CD released in PBS in N2</th>
<th>Time/ hours</th>
<th>cGMP production % of vehicle 1μM</th>
<th>cGMP production % of vehicle 10μM</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALF 186</td>
<td><img src="image1" alt="Structure" /></td>
<td>1.9</td>
<td>2.7</td>
<td>0</td>
<td>2</td>
<td>145.77 ± 30.7</td>
<td>127.78 ± 19.04</td>
</tr>
<tr>
<td>ALF409</td>
<td><img src="image2" alt="Structure" /></td>
<td>0.9</td>
<td>1.3</td>
<td>0.1</td>
<td>2</td>
<td>93.76 ± 10.23</td>
<td>89.45 ± 14.29</td>
</tr>
<tr>
<td>ALF411</td>
<td><img src="image3" alt="Structure" /></td>
<td>1.3</td>
<td>0.0</td>
<td>0.0</td>
<td>2</td>
<td>67.56 ± 11.98</td>
<td>84.81 ± 11.99</td>
</tr>
<tr>
<td>ALF432</td>
<td><img src="image4" alt="Structure" /></td>
<td>1.7</td>
<td>3.0</td>
<td>0.0</td>
<td>2</td>
<td>100.19 ± 2.34</td>
<td>86.60 ± 5.86</td>
</tr>
<tr>
<td>ALF436</td>
<td><img src="image5" alt="Structure" /></td>
<td>0.9</td>
<td>1.5</td>
<td>0.0</td>
<td>2</td>
<td>335.28* ± 108.57</td>
<td>152.42 ± 20.29</td>
</tr>
<tr>
<td>CORM-2</td>
<td><img src="image6" alt="Structure" /></td>
<td>0.0</td>
<td>0.0</td>
<td>--</td>
<td>2</td>
<td>231.32 ± 31.91</td>
<td>298.51* ± 82.82</td>
</tr>
<tr>
<td>CORM-3</td>
<td><img src="image7" alt="Structure" /></td>
<td>0.0</td>
<td>0.0</td>
<td>--</td>
<td>2</td>
<td>87.75 ± 8.14</td>
<td>102.53 ± 12.3</td>
</tr>
</tbody>
</table>

Table 1. Spontaneous Release of CO and cGMP production by CO-RMs.  

Molar equivalents of CO released by the indicated CO-RMs in RPMI/FBS or PBS. Experiments were performed at room temperature under normoxic and anoxic conditions. CO released in the headspace of a closed vial was determined by a gas chromatographic method that uses a thermal conductivity detector (GC-TCD). Confluent RASMC were treated with vehicle or a CO-releasing molecule (1 and 10μM) in the presence of IBMX for 15min. cGMP was extracted and measured as described. Data are expressed as percentage of respective vehicle which was set as 100%; n=8-12; *P<0.05 from vehicle.